What is the core difference between 503A and 503B?

503A pharmacies compound for a specific patient against a valid prescription. 503B outsourcing facilities can compound larger batches and distribute without patient-specific prescriptions in response to healthcare-provider orders — including for office stock — but they are subject to cGMP requirements, which 503A compounders generally are not.

That single difference — named-patient vs office stock — drives almost every downstream rule about who can sell, what can be compounded, and how it ships.

When does 503B apply to a peptide business?

503B is the realistic path for "doctor office stock," but with strict conditions: the facility must be FDA-registered and listed, operate under cGMP, and only use bulk substances on the 503B bulks list or compound drugs on FDA's shortage list at the relevant time. The product cannot be essentially a copy of a commercially available FDA-approved drug unless a narrow exception applies.

The wholesaling limit is the trap. The compounded drug cannot be sold or transferred by anyone other than the facility that made it. A peptide brand that buys 503B product and resells it to doctors steps outside the model.

When does 503A apply?

503A applies when a licensed physician evaluates a specific patient and writes a patient-specific prescription that a state-licensed pharmacy fills for that named patient. It is not a vehicle for stocking a clinic's shelf, and FDA restricts compounding drugs that are essentially copies of commercially available drugs — when a shortage resolves, FDA generally treats the drug as commercially available again.

How a compliant platform handles both

A defensible platform routes each order to the correct pathway and keeps them separate: office-stock orders to a 503B direct-to-clinic flow, named-patient prescriptions to a 503A flow. It does not let a clinic convert a 503A theory into bulk office stock, and it keeps the regulated facility or pharmacy as the seller of record.